Abiocode

Executive Summary

Abiocode is a privately held US biotechnology company founded in 2008 and headquartered in Thousand Oaks, California. Specializing in the production and distribution of high-quality research reagents—primarily antibodies and recombinant proteins—the company serves the global biomedical research community. Its product portfolio supports a wide range of applications including immunoblotting, ELISA, and chromatin immunoprecipitation (ChIP), and its reagents are frequently cited in leading scientific journals such as Nature, Science, and Cell. Despite its niche focus, Abiocode operates in a competitive market dominated by larger players like Thermo Fisher and Abcam. The company has not disclosed any funding rounds, valuation, or revenue, indicating its operations may be bootstrapped or privately financed. With no clear publicly available pipeline or stage information, Abiocode appears to maintain a steady, low-profile presence in the reagent supply sector. Given its established reputation in academic citations and a specialized product line, Abiocode likely generates recurring revenue from repeat customers in academic and pharmaceutical labs. However, the absence of disclosed commercial products, clinical development, or fundraising activity suggests limited near-term growth catalysts. The company's profile on BiopharmGuy lists it as a private entity with no employee range or trending rank, further underscoring its low public visibility. Competing on quality and specificity of reagents, Abiocode may benefit from increasing demand for reproducible research tools, but without tangible evidence of expansion or innovation, its investment appeal remains speculative. The conviction score is moderate, reflecting a stable but unremarkable business with no clear inflection points.

Upcoming Catalysts (preview)

• TBDPublication of High-Impact Studies Citing New Reagents60% success
• TBDExpansion of Product Catalog into Emerging Modalities (e.g., CRISPR-related antibodies)30% success
• TBDPartnership or Distribution Agreement with a Major Life Science Supplier15% success